GOVX Fundamental Analysis - GEOVAX LABS INC

Name: GEOVAX LABS INC (GOVX) Stock
Brand: GEOVAX LABS INC
Rating: 3.5 (3 reviews)

Fundamental Rating

GOVX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 533 industry peers in the Biotechnology industry. GOVX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, GOVX is valued expensive at the moment.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year GOVX has reported negative net income.

GOVX had a negative operating cash flow in the past year.

In the past 5 years GOVX always reported negative net income.

In the past 5 years GOVX always reported negative operating cash flow.

1.2 Ratios

Looking at the Return On Assets, with a value of -463.62%, GOVX is doing worse than 96.25% of the companies in the same industry.

GOVX has a Return On Equity of -879.26%. This is amonst the worse of the industry: GOVX underperforms 80.49% of its industry peers.

		Industry Rank	Sector Rank
ROA	-463.62%
ROE	-879.26%
ROIC	N/A

ROA(3y)-210.29%

ROA(5y)-163.35%

ROE(3y)-332.78%

ROE(5y)-290.99%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

GOVX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

GOVX does not have a ROIC to compare to the WACC, probably because it is not profitable.

GOVX has more shares outstanding than it did 1 year ago.

Compared to 5 years ago, GOVX has more shares outstanding

There is no outstanding debt for GOVX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

GOVX has an Altman-Z score of -47.48. This is a bad value and indicates that GOVX is not financially healthy and even has some risk of bankruptcy.

The Altman-Z score of GOVX (-47.48) is worse than 92.87% of its industry peers.

There is no outstanding debt for GOVX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-47.48

ROIC/WACCN/A

WACC8.77%

2.3 Liquidity

GOVX has a Current Ratio of 2.03. This indicates that GOVX is financially healthy and has no problem in meeting its short term obligations.

GOVX has a worse Current ratio (2.03) than 74.86% of its industry peers.

A Quick Ratio of 2.03 indicates that GOVX has no problem at all paying its short term obligations.

With a Quick ratio value of 2.03, GOVX is not doing good in the industry: 73.17% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
Current Ratio	2.03
Quick Ratio	2.03

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 92.57% over the past year.

GOVX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 27.45% yearly.

EPS 1Y (TTM)92.57%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%65.93%

Revenue 1Y (TTM)N/A

Revenue growth 3Y117.28%

Revenue growth 5Y27.45%

Sales Q2Q%-100%

3.2 Future

Based on estimates for the next years, GOVX will show a very strong growth in Earnings Per Share. The EPS will grow by 32.77% on average per year.

GOVX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 278.07% yearly.

EPS Next Y76.85%

EPS Next 2Y33.03%

EPS Next 3Y32.77%

EPS Next 5YN/A

Revenue Next Year-56.94%

Revenue Next 2Y-41.42%

Revenue Next 3Y278.07%

Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

GOVX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GOVX. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as GOVX's earnings are expected to grow with 32.77% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y33.03%

EPS Next 3Y32.77%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for GOVX!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

GEOVAX LABS INC

NASDAQ:GOVX (11/19/2025, 12:39:29 PM)

0.4019

-0.01 (-1.5%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)11-13 2025-11-13/amc

Earnings (Next)03-25 2026-03-25/amc

Inst Owners2.18%

Inst Owner Change155.26%

Ins Owners0.49%

Ins Owner Change9.38%

Market Cap11.94M

Revenue(TTM)3.95M

Net Income(TTM)-24.81M

Analysts81.82

Price Target10.1 (2413.06%)

Short Float %11.16%

Short Ratio3.65

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)19.25%

Min EPS beat(2)4.68%

Max EPS beat(2)33.82%

EPS beat(4)4

Avg EPS beat(4)34.96%

Min EPS beat(4)4.68%

Max EPS beat(4)61.7%

EPS beat(8)6

Avg EPS beat(8)-21.58%

EPS beat(12)8

Avg EPS beat(12)-17.72%

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)2

Avg Revenue beat(2)77.25%

Min Revenue beat(2)26.69%

Max Revenue beat(2)127.81%

Revenue beat(4)3

Avg Revenue beat(4)71.93%

Min Revenue beat(4)-64.4%

Max Revenue beat(4)197.61%

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)0%

EPS NQ rev (3m)23.19%

EPS NY rev (1m)0%

EPS NY rev (3m)21.74%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)0%

Revenue NY rev (3m)3.68%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	1.94
P/FCF	N/A
P/OCF	N/A
P/B	4.23
P/tB	4.23
EV/EBITDA	N/A

EPS(TTM)-1.41

EYN/A

EPS(NY)-1.31

Fwd EYN/A

FCF(TTM)-0.92

FCFYN/A

OCF(TTM)-0.92

OCFYN/A

SpS0.21

BVpS0.09

TBVpS0.09

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-463.62%
ROE	-879.26%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-210.29%

ROA(5y)-163.35%

ROE(3y)-332.78%

ROE(5y)-290.99%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score5

Asset Turnover1.15

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	56.29%
Cap/Sales	0.79%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	2.03
Quick Ratio	2.03
Altman-Z	-47.48

F-Score5

WACC8.77%

ROIC/WACCN/A

Cap/Depr(3y)108.76%

Cap/Depr(5y)249.22%

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)92.57%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%65.93%

EPS Next Y76.85%

EPS Next 2Y33.03%

EPS Next 3Y32.77%

EPS Next 5YN/A

Revenue 1Y (TTM)N/A

Revenue growth 3Y117.28%

Revenue growth 5Y27.45%

Sales Q2Q%-100%

Revenue Next Year-56.94%

Revenue Next 2Y-41.42%

Revenue Next 3Y278.07%

Revenue Next 5YN/A

EBIT growth 1Y8.13%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-83000.3%

EBIT Next 3Y649.13%

EBIT Next 5YN/A

FCF growth 1Y-32.11%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-32.36%

OCF growth 3YN/A

OCF growth 5YN/A

GEOVAX LABS INC / GOVX FAQ

Can you provide the ChartMill fundamental rating for GEOVAX LABS INC?

ChartMill assigns a fundamental rating of 3 / 10 to GOVX.

Can you provide the valuation status for GEOVAX LABS INC?

ChartMill assigns a valuation rating of 1 / 10 to GEOVAX LABS INC (GOVX). This can be considered as Overvalued.

How profitable is GEOVAX LABS INC (GOVX) stock?

GEOVAX LABS INC (GOVX) has a profitability rating of 0 / 10.

What is the expected EPS growth for GEOVAX LABS INC (GOVX) stock?

The Earnings per Share (EPS) of GEOVAX LABS INC (GOVX) is expected to grow by 76.85% in the next year.

GEOVAX LABS INC (GOVX) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

GEOVAX LABS INC / GOVX FAQ

Can you provide the ChartMill fundamental rating for GEOVAX LABS INC?

Can you provide the valuation status for GEOVAX LABS INC?

How profitable is GEOVAX LABS INC (GOVX) stock?

What is the expected EPS growth for GEOVAX LABS INC (GOVX) stock?